Durysta market size?

Durysta-specific market size numbers aren’t publicly disclosed. AbbVie/Allergan does not break out Durysta revenue separately, and market research firms typically publish the size of the broader glaucoma drug market rather than a standalone figure for Durysta.

Useful context:
- The global glaucoma/IOP-lowering drug market is a multi-billion-dollar space (roughly in the low-to-mid tens of billions range across various reports in recent years), with growth driven by adherence challenges and new delivery options.
- Durysta is a niche, first-in-class intracameral implant, so its standalone sales are a fraction of the overall market and depend on uptake, payer acceptance, and how many patients convert from daily eye drops to the implant.

Rough way to think about potential:
- If Durysta captures a small share of the prostaglandin/IOP-lowering segment over several years, annual revenue could be in the tens to low hundreds of millions of USD range. Larger shares (over 5–10%) would imply hundreds of millions to a bit more, depending on pricing and usage assumptions.
- Actual figures will depend on geography (U.S. vs. international uptake), pricing per implant, and how many implants are administered per patient per year.

If you’d like, I can look for the latest analyst estimates or provide a more precise framework to estimate market size using assumed adoption rates, patient populations, and implant pricing. Also, tell me whether you want global or U.S.-only figures.